0001209191-14-030387.txt : 20140501 0001209191-14-030387.hdr.sgml : 20140501 20140501194420 ACCESSION NUMBER: 0001209191-14-030387 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140501 FILED AS OF DATE: 20140501 DATE AS OF CHANGE: 20140501 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 617-513-9882 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Todd C CENTRAL INDEX KEY: 0001579179 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 14806606 MAIL ADDRESS: STREET 1: C/O EVOKE PHARMA, INC. STREET 2: 12555 HIGH BLUFF DR SUITE 385 CITY: SAN DIEGO STATE: CA ZIP: 92130 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2014-05-01 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001579179 Brady Todd C C/O ALDEYRA THERAPEUTICS, INC. 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803 1 1 0 0 President and CEO Common Stock 2589 D Employee Stock Option (Right to Buy) 0.552 2023-09-07 Common Stock 192084 D Employee Stock Option (Right to Buy) 0.552 2023-09-07 Common Stock 32953 D Employee Stock Option (Right to Buy) 0.552 2023-09-07 Common Stock 48021 D Employee Stock Option (Right to Buy) 4.56 2023-10-29 Common Stock 96042 D Exercisable over four years of service from April 15, 2013, with 25% vesting upon completion of 12 months of service and in 36 equal monthly installments thereafter. This option became exercisable with respect to 1/6th of the shares each month over six months of continuous service following April 1, 2013. Exercisable with respect to 16,007 shares upon each of the effective date of the initial public offering, the date on which the Issuer's closing market capitalization equals at least $55.0 million for 10 consecutive trading days and the date on which the Issuer's closing market capitalization equals at least $70.0 million for 10 consecutive trading days, provided that Dr. Brady remains in continuous service with the Issuer through each such date. Exercisable with respect to 1/16th of the shares in quarterly installments over four years of continuous service following October 30, 2013. /s/ Todd C. Brady 2014-05-01